Aptamer Conjugated RNA/DNA Hybrid Nanostructures Designed for Efficient Regulation of Blood Coagulation

Methods Mol Biol. 2023:2709:277-286. doi: 10.1007/978-1-0716-3417-2_19.

Abstract

Disruptions to the hemostatic pathway can cause a variety of serious or even life-threatening complications. Situations in which the coagulation of blood has become disturbed necessitate immediate care. Thrombin-binding aptamers are single-stranded nucleic acids that bind to thrombin with high specificity and affinity. While they can effectively inhibit thrombin, they suffer from rapid degradation and clearance in vivo. These issues are resolved, however, by attaching the therapeutic aptamer to a nucleic acid nanostructure. The increased size of the nanostructure-aptamer complex elongates the post-infusion half-life of the aptamer. These complexes are also immunoquiescent. A significant benefit of using nucleic acids as anticoagulants is their rapid deactivation by the introduction of a nanostructure made fully from the reverse complement of the therapeutically active nanostructure. These advantages make nanoparticle conjugated antithrombin aptamers a promising candidate for a rapidly reversible anticoagulant therapy.

Keywords: Anticoagulant; Aptamer; RNA/DNA hybrid; Thrombin.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Anticoagulants / chemistry
  • Anticoagulants / pharmacology
  • Aptamers, Nucleotide* / chemistry
  • Blood Coagulation
  • DNA / chemistry
  • Nanostructures*
  • RNA / pharmacology
  • Thrombin / metabolism

Substances

  • Thrombin
  • RNA
  • Anticoagulants
  • Aptamers, Nucleotide
  • DNA